drugset / Trial / NCT01128543
Lapatinib in Combination With Vinorelbine
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is a Multicenter, Open-Label, Phase II Study of lapatinib in Combination with Vinorelbine in women with documented evidence of HER2/neu positive breast cancer which is metastatic or recurrent and with or without prior chemotherapy or anti-HER2/neu targeted therapy in the metastatic and relaps setting.
Timeline
- Start
- 2009-04
- Primary completion
- 2012-03
- Completion
- 2012-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Lapatinib | Small molecule | 1250 mg | — |
| Comparator | Vinorelbine | Small molecule | 25 mg/m2 | Intravenous |